China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of a Series C financing round, raising USD 50 million. The funds will be used to advance overseas clinical studies for multiple innovative drugs, positioning the company for global expansion.
Company Background and Pipeline
Founded in 2014, TargetRx has established a strong pipeline of leading products. TGRX-678 is a fourth-generation BCR-ABL1 molecule with a novel mechanism of action, targeting chronic myeloid leukemia (CML). TGRX-326 is a third-generation EML4-ALK inhibitor. Both products are currently in well-advanced clinical trials, highlighting TargetRx’s commitment to addressing significant unmet needs in oncology.
Future Outlook
With the successful completion of the Series C financing, TargetRx is poised to accelerate its global clinical development efforts. The funding will support the advancement of TGRX-678 and TGRX-326, further solidifying TargetRx’s position as a leader in the development of next-generation kinase inhibitors.-Fineline Info & Tech
